Although drugs targeting ATF4-Gln axis (e.g., DHA [dihydroartemisinin] inducing ATF4 degradation, SLC1A5 monoclonal antibodies) show efficacy in preclinical studies, they face challenges including metabolic plasticity, tumor heterogeneity, and toxicity to normal tissues. Here, ATF4 is linked to neoplasm.